GF CSI Innovative Drugs Industry ETF

Fosun Pharma Subsidiary's Levofloxacin Injection Approved

Fosun Pharma's Hengrui Medicine Receives Approval for Phase I Clinical Trial of HLX48 for Solid Tumors

2025 Top 10 Domestic Innovative Drug Companies Revenue Surpasses 100 Billion, BeiGene Leads Turnaround

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

NMPA Officially Releases 'Implementation Measures for Drug Trial Data Protection'

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

159638

159558

516320

159835

515120

588200

512480

Since 2026, foreign institutions' research on A-share listed companies has continued to heat up. According to Wind statistics, as of April 10 this year, foreign institutions have conducted nearly 1,400 research visits to Shanghai Stock Exchange companies, covering about 190 companies, with a focus on sectors such as semiconductors, high-end equipment, smart hardware, and innovative drugs. Against the backdrop of increasing global uncertainty, the intensive research by foreign institutions on A-share companies highlights their emphasis on and recognition of the safety and stability of Chinese assets. (Securities Times)

36Kr

Harvest CSI High-End Equipment Subdivision 50 ETF

E Fund CSI Semiconductor Material & Equipment Thematic ETF

ChinaAMC CSI Equipment Industry ETF

CCB Principal CSI Innovative Drugs Industry ETF

Harvest SSE STAR Chip ETF

GTJA Allianz CSI All Share Semiconductors & Semiconductor Equipment ETF

In the year to date, foreign institutions have conducted nearly 1,400 research visits to companies listed on the Shanghai Stock Exchange, focusing primarily on sectors such as semiconductors and high-end equipment

159992

159297

517380

The National Healthcare Security Administration has released a new policy, stating that the pricing mechanism for innovative drugs will no longer solely rely on price reductions, but will instead be dynamically adjusted through a combination of marketization and government regulation. The new mechanism emphasizes multiple factors such as clinical demand, research and development difficulty, and corporate willingness, encouraging companies to set their own prices and promoting reasonable returns for innovative drugs. This policy will change the negotiation strategies of pharmaceutical companies with healthcare insurance, enhance market vitality, and drive industry development

腾讯新闻 - 财经

Yinhua CSI Innovative Drugs Industry ETF

China Southern CNI HK Connect Innovative Drug ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

Good news for innovative drugs! Medical insurance pricing will no longer solely focus on price cuts, but will be dynamically adjusted

688166

159837

560600

510660

159316

159858

588860

512010

On April 15th, China's innovative drug sector collectively rose, with companies like BrightGene experiencing significant growth. The State Council released new policies to optimize the pricing mechanism for innovative drugs, and it is expected that the Class C catalog for medical insurance will be published in 2025, marking the arrival of the incremental payment era for innovative drugs. Huafu Securities predicts that the total transaction volume for innovative drug BD will increase from USD 9.2 billion in 2020 to USD 52.3 billion in 2025, with overseas licensing transaction volume exceeding USD 130 billion by 2025. At the ASCO conference, the number of oral presentations from China reached a historic high, demonstrating the potential and attention surrounding the innovative drug market

BrightGene

E Fund CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Southern CSI Brand Name Drug Industry ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Penghua CSI HK Connect Health Care Composite ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Sector uplift, the leap and journey of Chinese innovative drugs

589720

159286

560900

159622

516060

New State Council policies explicitly establish a 'price protection period' for innovative drugs, allowing high-level innovative drugs to set their own prices during the initial launch phase and enjoy this protection period. Centralized procurement will not touch innovative drugs, while a diversified commercial insurance payment system simultaneously opens up new space. Stimulated by this news, the A-share innovative drug sector surged strongly in the afternoon session, with multiple stocks hitting the limit up. Brokerage firms point out that the convergence of earnings realization, valuation repair, and policy catalysts may have ushered in a new wave of market activity for the innovative drug sector

Wallstreetcn

Guotai SSE STAR Brand Name Drug ETF

Penghua CNI HK Connect Innovative Drugs ETF

J.P.Morgan Asset Management CSI Brand Name Drug Industry ETF

E Fund CSI Innovative Drugs ETF

Eastmoney Fund CSI SH-HK-SZ Brand Name Drug Industry ETF

Harvest CSI Hong Kong Connect Innovative Drugs ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

ICBCCS CSI Brand Name Drug Industry ETF

PKU HEALTHCARE

SL PHARM

HPGC

HISUN

Hvsen Biotech

YKYY

Staidson BioPharm

Hengrui Pharma

HENGRUI PHARMA

BeOne Medicines

BEONE MEDICINES

InnoCare Pharma

INNOCARE

RemeGen

REMEGEN

Shenwan Hongyuan

SWHY

SHCF

Beigene

SWHYHK

Explosive Growth in Innovative Drugs: Top-Level Pricing Mechanism Reform, Who Will Be the Biggest Winner?

800医药

In the first quarter of 2026, China's innovative drug industry performed exceptionally well, with the total amount of out-licensing transactions exceeding USD 60 billion, nearly half of the total for the entire year of 2025. The National Medical Products Administration approved 13 innovative drugs for market launch, of which 6 are first-in-class drugs, covering key disease areas. The total number of innovative drugs under research in China reached 4,751, accounting for 33.7% of the global total, with over 45% in several cutting-edge fields. China has become the world's largest country for innovative drugs under research, with transaction volume accounting for 49% of the global total

Yinhua CNI HK Connect Innovative Drugs ETF

JPMorgan Chase

INNOVENT BIO

Eli Lilly

CSPC PHARMA

AstraZeneca

CITIC Securities Co., Ltd.

CITIC SEC

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

AstraZeneca PLC

Mindset Observation Institute: In the first quarter, China's innovative drugs delivered an exciting report card

The General Office of the State Council issued "Several Opinions on Improving the Price Formation Mechanism for Pharmaceuticals," establishing a pricing governance logic for drugs centered on clinical value and innovation level. Experts indicate that this policy provides stable expectations and autonomous pricing space for the innovative drug industry, promoting industry profitability. In the first quarter, the total amount of external licensing transactions for innovative drugs exceeded USD 60 billion, and the innovative drug sectors in both the A-share and Hong Kong markets rebounded strongly. Despite the favorable policy, the contradictions between medical insurance payments and hospital usage still need to be resolved

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Ping An CSI HK Equities Medical and Health Integration ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

CICC

From "Medical Insurance Negotiation Price Reduction" to "Self-Determined Pricing Protection": The drug price formation mechanism directly addresses the biggest pain point, and innovative drugs welcome a return to value

300医药

Since September last year, the pharmaceutical sector has undergone a deep adjustment, with the CSI 300 Pharmaceutical Index retreating over 18%. Recently, the pharmaceutical sector has shown strength against the trend, with some leading companies' stock prices reaching new highs. Analysis indicates that the pharmaceutical sector may have bottomed out, with marginal improvements in valuation and fundamentals. Future investments should focus on the innovative drug field, and although the macro environment remains uncertain in the short term, investment strategies should emphasize structural opportunities

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Has the pharmaceutical sector hit bottom this time? Which directions are worth paying attention to?

300149

On April 1st, all three major A-share indices rose by more than 1%, with innovative drug concept stocks collectively increasing, and multiple stocks such as ChemPartner hitting the daily limit. The upcoming 2026 American Association for Cancer Research Annual Meeting has become a catalyst for market enthusiasm. Huayuan Securities pointed out that China's pharmaceutical industry has completed the transition from generics to innovation, with innovative drugs becoming a new engine for industry growth. Future investments should focus on innovative drug companies with global competitiveness and cutting-edge technology directions

ChemPartner

April starts with a bang, the innovative drug concept collectively explodes, ChemPartner hits the 20% daily limit up

GF CSI Innovative Drugs Industry ETF(515120.SH)